0RK9 logo

Alligator Bioscience AB (publ)LSE:0RK9 Stock Report

Market Cap SEK 29.6m
Share Price
SEK 0.70
n/a
1Y-99.9%
7D-39.7%
Portfolio Value
​
View

Alligator Bioscience AB (publ)

LSE:0RK9 Stock Report

Market Cap: SEK 29.6m

Alligator Bioscience (0RK9) Stock Overview

A research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Finland and Sweden. More details

0RK9 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Risk Analysis

Has less than 1 year of cash runway

Does not have a meaningful market cap (SEK30M)

Highly volatile share price over the past 3 months compared to the UK market

Negative shareholders equity

+ 3 more risks

0RK9 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Alligator Bioscience AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Alligator Bioscience
Historical stock prices
Current Share PriceSEK 0.70
52 Week HighSEK 589.00
52 Week LowSEK 0.68
Beta1.53
1 Month Change-53.89%
3 Month Change-83.77%
1 Year Change-99.87%
3 Year Changen/a
5 Year Changen/a
Change since IPO-100.00%

Recent News & Updates

Recent updates

Shareholder Returns

0RK9GB BiotechsGB Market
7D-39.7%2.2%0.8%
1Y-99.9%11.2%15.3%

Return vs Industry: 0RK9 underperformed the UK Biotechs industry which returned 11.2% over the past year.

Return vs Market: 0RK9 underperformed the UK Market which returned 15.3% over the past year.

Price Volatility

Is 0RK9's price volatile compared to industry and market?
0RK9 volatility
0RK9 Average Weekly Movement30.5%
Biotechs Industry Average Movement6.3%
Market Average Movement4.9%
10% most volatile stocks in GB Market10.6%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0RK9's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0RK9's weekly volatility has decreased from 56% to 30% over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
200013Søren Bregenholtwww.alligatorbioscience.se

Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Finland and Sweden. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 2 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage for the treatment of solid metastatic tumors. It also offers ALG

Alligator Bioscience AB (publ) Fundamentals Summary

How do Alligator Bioscience's earnings and revenue compare to its market cap?
0RK9 fundamental statistics
Market capSEK 29.57m
Earnings (TTM)-SEK 77.72m
Revenue (TTM)SEK 46.22m
0.6x
P/S Ratio
-0.4x
P/E Ratio

Is 0RK9 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0RK9 income statement (TTM)
RevenueSEK 46.22m
Cost of RevenueSEK 106.63m
Gross Profit-SEK 60.41m
Other ExpensesSEK 17.31m
Earnings-SEK 77.72m

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

Feb 12, 2026

Earnings per share (EPS)-1.77
Gross Margin-130.70%
Net Profit Margin-168.15%
Debt/Equity Ratio0%

How did 0RK9 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/27 01:50
End of Day Share Price 2025/11/25 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alligator Bioscience AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Carl RamaniusRedeye
Filip LindkvistRedeye